U.S. markets open in 7 hours 3 minutes
  • S&P Futures

    3,667.50
    +0.25 (+0.01%)
     
  • Dow Futures

    29,873.00
    +5.00 (+0.02%)
     
  • Nasdaq Futures

    12,484.50
    +30.25 (+0.24%)
     
  • Russell 2000 Futures

    1,835.70
    -1.80 (-0.10%)
     
  • Crude Oil

    45.20
    -0.08 (-0.18%)
     
  • Gold

    1,838.50
    +8.30 (+0.45%)
     
  • Silver

    24.17
    +0.09 (+0.37%)
     
  • EUR/USD

    1.2127
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    0.9480
    0.0000 (0.00%)
     
  • Vix

    21.17
    +0.40 (+1.93%)
     
  • GBP/USD

    1.3399
    +0.0023 (+0.17%)
     
  • USD/JPY

    104.3880
    -0.0360 (-0.03%)
     
  • BTC-USD

    19,063.20
    -18.15 (-0.10%)
     
  • CMC Crypto 200

    373.13
    +8.22 (+2.25%)
     
  • FTSE 100

    6,463.39
    +78.66 (+1.23%)
     
  • Nikkei 225

    26,809.37
    +8.39 (+0.03%)
     

Insider Buying: John Bailey Just Spent US$102k On G1 Therapeutics, Inc. (NASDAQ:GTHX) Shares

Simply Wall St
·3 min read

Potential G1 Therapeutics, Inc. (NASDAQ:GTHX) shareholders may wish to note that insider John Bailey recently bought US$102k worth of stock, paying US$12.80 for each share. However, it only increased shareholding by a small percentage, and it wasn't a huge purchase by absolute value, either.

Check out our latest analysis for G1 Therapeutics

The Last 12 Months Of Insider Transactions At G1 Therapeutics

In fact, the recent purchase by John Bailey was the biggest purchase of G1 Therapeutics shares made by an insider individual in the last twelve months, according to our records. That means that even when the share price was higher than US$12.78 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.

In the last twelve months G1 Therapeutics insiders were buying shares, but not selling. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
insider-trading-volume

G1 Therapeutics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Insiders own 1.5% of G1 Therapeutics shares, worth about US$7.4m, according to our data. Whilst better than nothing, we're not overly impressed by these holdings.

So What Do The G1 Therapeutics Insider Transactions Indicate?

It is good to see recent purchasing. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that G1 Therapeutics insiders are expecting a bright future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. At Simply Wall St, we've found that G1 Therapeutics has 3 warning signs (1 shouldn't be ignored!) that deserve your attention before going any further with your analysis.

Of course G1 Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.